Format

Send to

Choose Destination
J Infect Dis. 2016 Feb 15;213(4):556-60. doi: 10.1093/infdis/jiv433. Epub 2015 Sep 2.

Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy.

Author information

1
University of Pittsburgh, Pennsylvania.
2
Center for Biostatistics in AIDS Research, Harvard School of Public Health.
3
Social and Scientific Systems, Silver Spring, Maryland.
4
University of California-San Diego.
5
University of North Carolina-Chapel Hill.
6
Massachusetts General Hospital, Boston Ragon Institute, Cambridge, Massachusetts.

Abstract

We measured plasma human immunodeficiency virus type 1 (HIV-1) RNA levels by means of single-copy assay in 334 participants receiving virologically suppressive antiretroviral therapy (ART). A residual viremia load of ≥1 copy/mL after 4 years of ART was predicted by a higher pre-ART HIV-1 RNA level, higher CD8(+) T-cell count during treatment, and a lower ratio of CD4+ T cells to CD8+ T cells during treatment but not by initial ART regimen. In a longitudinal subset of 64 individuals, continued decay of the plasma HIV-1 RNA level was observed, with an average annual decrease of 6% and an estimated half-life of 11.5 years. In contrast to prior reports, the persistent viremia level continues to slowly decline during years 4-12 of suppressive ART.

CLINICAL TRIALS REGISTRATION:

NCT00001137.

KEYWORDS:

CD4/CD8 ratio; HIV/AIDS; residual viremia; single-copy assay; viral decay

PMID:
26333941
PMCID:
PMC4721905
DOI:
10.1093/infdis/jiv433
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Secondary source ID, Grant support

Publication types

MeSH terms

Substances

Secondary source ID

Grant support

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center